Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.29703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
Int J Hematol
December 2024
Department of Hematology, Saiseikai Yokohama Nanbu Hospital, 3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, 234-0054, Japan.
Nuclear receptor profiling for subtype classification and as prognostic markers in 33 cancer types.
Discov Oncol
December 2024
Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Nuclear receptors, a group of 48 transcription factors that regulate a multitude of processes within our body, have long been employed as diagnostic markers or therapeutic targets in breast cancer, prostate cancer, and acute promyelocytic leukemia. Unfortunately, no comprehensive investigation has been conducted on their significance in other cancer types. The current study aimed to explore novel diagnostic markers by classifying nuclear receptors according to their expression patterns based on transcriptome data from The Cancer Genome Atlas on 10,071 tumor samples across 33 cancer types and investigating their association with genetic mutations, histological types, and prognosis.
View Article and Find Full Text PDFATRA-induced NEAT1 upregulation promotes autophagy during APL cell granulocytic differentiation.
PLoS One
December 2024
Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Aims: Acute promyelocytic leukemia (APL) progresses quickly and often leads to early hemorrhagic death. Treatment with all-trans retinoic acid (ATRA) promotes differentiation of APL cells and clinical remission, making APL a potentially curable malignancy. Understanding how ATRA works may lead to new treatments for other types of leukemia.
View Article and Find Full Text PDFPain crisis complicating severe bone marrow necrosis during induction for acute promyelocytic leukaemia.
Pathology
November 2024
Department of Haematology, Monash Health, Clayton, Vic, Australia; Department of Medicine, School of Clinical Sciences at Monash Health, Clayton, Vic, Australia.
Induction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial.
Trials
December 2024
Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: The treatment of all-trans retinoic acid (ATRA) and arsenical agent has revolutionarily improved the prognosis of acute promyelocytic leukemia (APL) both in adults and children. Nevertheless, coagulation disorder and differentiation syndrome (DS) are the main causes of early death in APL patients. Early chemotherapy to reduce leukocytes during induction is an important measure to reduce complications and mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!